Category: Histopathology

All Podcast Categories
S4-23 - Stephen Harrison on Challenges and Opportunities in NASH Drug Development

S4-23 – Stephen Harrison on Challenges and Opportunities in NASH Drug Development

Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. The group dives deep into a range of topics including drugs with strong metabolic foundations, the state of histopathology, clinical trial design and screen fail rates, FDA ADCOM on obeticholic acid and much more.

S4-19.4 - Patient Advocates Describe the Reasoning Behind Their Testimonies

S4-19.4 – Patient Advocates Describe the Reasoning Behind Their Testimonies

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the panelists dive into why they shared their specific testimonies among other takeaways.

S4-19.3 - The Role of Biopsy in Prescribing NASH Therapeutics

S4-19.3 – The Role of Biopsy in Prescribing NASH Therapeutics

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the group discusses the role of biopsy, drug trial endpoints and more.

S4-19.2 - Patient Advocates React to the Word “Empathy”

S4-19.2 – Patient Advocates React to the Word “Empathy”

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.

S4-19.1 - How Did the Patient Advocates Come to Offer Testimonies?

S4-19.1 – How Did the Patient Advocates Come to Offer Testimonies?

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This opening conversation reveals how each guest became involved in the process and offers a preview of their reactions to the experience.

S2-4 - What Can You Do Today to Prevent and Treat Fatty Liver Disease?

S2-4 – What Can You Do Today to Prevent and Treat Fatty Liver Disease?

Ken Cusi and Roger Green are joined by Diana Barb and Jay Shubrook in a discussion around effective therapies and strategies for fighting fatty liver disease that are available now. The group discusses frontline screening, medications, bariatric surgery, lifestyle management, practical insights and much more.

S4-19 - Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

S4-19 – Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session regarding the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.

S4-18.6 - From the Vault: Clinical Care Pathway: What Can Be Done Today?

S4-18.6 – From the Vault: Clinical Care Pathway: What Can Be Done Today?

Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation From the Vault answers the question “What Can Be Done Today?” in terms of screening and patient management without approved drugs.

Experience Nudge Learning! Interested in a new way of learning?